1. Home
  2. ACIU vs AFRI Comparison

ACIU vs AFRI Comparison

Compare ACIU & AFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACIU
  • AFRI
  • Stock Information
  • Founded
  • ACIU 2003
  • AFRI 1943
  • Country
  • ACIU Switzerland
  • AFRI Gibraltar
  • Employees
  • ACIU N/A
  • AFRI N/A
  • Industry
  • ACIU Biotechnology: Pharmaceutical Preparations
  • AFRI Packaged Foods
  • Sector
  • ACIU Health Care
  • AFRI Consumer Staples
  • Exchange
  • ACIU Nasdaq
  • AFRI Nasdaq
  • Market Cap
  • ACIU 213.3M
  • AFRI 207.7M
  • IPO Year
  • ACIU 2016
  • AFRI N/A
  • Fundamental
  • Price
  • ACIU $2.46
  • AFRI $8.82
  • Analyst Decision
  • ACIU Strong Buy
  • AFRI
  • Analyst Count
  • ACIU 2
  • AFRI 0
  • Target Price
  • ACIU $10.00
  • AFRI N/A
  • AVG Volume (30 Days)
  • ACIU 136.3K
  • AFRI 13.1K
  • Earning Date
  • ACIU 11-04-2025
  • AFRI 04-30-2025
  • Dividend Yield
  • ACIU N/A
  • AFRI N/A
  • EPS Growth
  • ACIU N/A
  • AFRI N/A
  • EPS
  • ACIU N/A
  • AFRI N/A
  • Revenue
  • ACIU $36,362,036.00
  • AFRI $274,223,000.00
  • Revenue This Year
  • ACIU N/A
  • AFRI N/A
  • Revenue Next Year
  • ACIU $1,022.98
  • AFRI N/A
  • P/E Ratio
  • ACIU N/A
  • AFRI N/A
  • Revenue Growth
  • ACIU 86.71
  • AFRI N/A
  • 52 Week Low
  • ACIU $1.43
  • AFRI $7.47
  • 52 Week High
  • ACIU $3.98
  • AFRI $11.74
  • Technical
  • Relative Strength Index (RSI)
  • ACIU 60.92
  • AFRI 64.98
  • Support Level
  • ACIU $2.12
  • AFRI $8.21
  • Resistance Level
  • ACIU $2.35
  • AFRI $8.87
  • Average True Range (ATR)
  • ACIU 0.14
  • AFRI 0.40
  • MACD
  • ACIU 0.04
  • AFRI 0.01
  • Stochastic Oscillator
  • ACIU 76.79
  • AFRI 70.85

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About AFRI Forafric Global PLC

Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.

Share on Social Networks: